依达拉奉联合低分子肝素治疗进展性脑梗死疗效观察

Clinical observation on the effet of edaravone combined with low-molecular-weight heparin on progressive cerebral infarction

目的观察低分子肝素联合依达拉奉治疗进展性脑梗死的疗效。方法将发病72h内的进展性脑梗死患者60例随机分成低分子肝素与依达拉奉联合治疗组和单用低分子肝素治疗对照组各30例，于治疗前、后进行神经功能缺损程序评分（NIHSS）和日常生活能力量表（ADL）评分及临床疗效评定。结果两组治疗前NIHSS、ADL评分差异均无统计学意义（均P〉0．05）；治疗后7d、14d两组NIHSS差异均有统计学意义（t=15．987、11．756，均P〈0．01），治疗后14d，两组ADL评分差异有统计学意义（t=62．56，P〈0．01）。治疗后14d，治疗组显效率63．3％、总有效率83．3％，明显高于对照组的20．0％、46．7％x2=13．695、5．769，均P〈0．01）。结论低分子肝素联合依达拉奉治疗进展性脑梗死有显著疗效。

Objective To study the clinical effect of low-molecular-weight heparin combined with edaravone in the treatment of progressive cerebral infarction. Methods 60 patients with acute progressive cerebral infarction in 72 hours were randomly divided into treatment group received edaravone combined low-molecular-weight heparin（n = 30） and control group received low-molecular-weight heparin（n = 30）. The primary efficacy was evaluated by NIHSS （the National Institutes of Health Stroke Scale）. ADL（ Activities of daily living） and clinical effect. Results Our study showed that the score of NIHSS on 7th day post-therapy and 14th day post-therapy in treatment group was lower than that in control group （ t = 15. 987 and 11. 756, both P 〈 0.01 ）. However, the score of ADL in the theatment group on 14th day post-therapy was higher than that of control group （ t = 62.56, P 〈 0.01 ）. The overall clinical response rate of treatment group was higher than that of control group（ x2 = 13. 695,5. 769, all P 〈 0.01 ）. Conclusion Edara- vone combined with low-molecular-weight heparin has remakable effect on the treatment of progressive cerebral infarcti.